Liz Highleyman

A quarter of study participants accounted for three-quarters of newly diagnosed cases of chlamydia, gonorrhea and syphilis.

Survey shows few at-risk gay and bi men had received the vaccine, which can prevent anal and other cancers.

Leronlimab (PRO 140) also shows promise as a treatment for cancer and graft-versus-host disease.

Final results from the PARTNER 2 study of gay and bi men confirm that undetectable equals untransmittable.

Researchers have developed a new gene therapy approach for children with severe combined immunodeficiency.

The number of HIV-positive Medicare recipients with liver disease is rising, almost entirely as a result of NAFLD

Descovy and Truvada were both highly effective and generally safe options for HIV prevention in a recent clinical trial.

Informal PrEP users were more likely to take it intermittently and skip recommended medical tests.

Steve Spencer—now on treatment with an undetectable viral load—says evidence of PrEP’s effectiveness is still clear.

A third of at-risk gay and bi men are now using Truvada for HIV prevention, the CDC says.

Ned Sharpless has been appointed interim head of the regulatory agency after the unexpected resignation of the commissioner.

People with commercial insurance stayed on PrEP about twice as long as those covered by Medicaid.

HIV-positive people with a higher viral load over a longer period appear more likely to develop hepatocellular carcinoma.

Truvada and Descovy are both highly effective and generally safe options for HIV prevention.

A study in Botswana showed that women with HIV had shorter survival than HIV-negative women with breast cancer.